DAYTON, Ohio, Aug. 6, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX) today announced that Eurand Inc. and UCB, Inc. have settled long-running litigation concerning a 1999 development, license and supply agreement between the two companies for a sustained-release formulation of methylphenidate hydrochloride (MPH) co-developed by Eurand and currently marketed by UCB under the brand names Metadate(r) CD and Equasym(r) XL for the treatment of Attention Deficit Hyperactivity Disorder.
